In addition, the secondary tumors resemble the phenotype (morphology and ESA/CD44/CD24 expression profile) of the initial tumor and the tumorigenic ESA+CD44+CD24− tumor cells could be serially passaged at least four passages in vivo. This evidence concerns the gene CD24 and neoplasm.